What is the half-life of dobutamine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Dobutamine

The plasma half-life of dobutamine is 2 minutes. 1

Pharmacokinetic Profile

  • Elimination half-life: Approximately 2 minutes in adults, full-term neonates, and older children 1, 2, 3, 4
  • Onset of action: Within 1-2 minutes of intravenous infusion 1
  • Time to peak effect: Up to 10 minutes may be required to achieve the peak hemodynamic effect at any given infusion rate 1
  • Duration of action: Approximately 10 minutes after discontinuation 4

Special Population Considerations

  • Preterm infants: The elimination half-life may be prolonged to 4-5 minutes due to physiologic immaturity 3
  • Pediatric patients: The clearance of dobutamine varies widely depending on age, though the half-life remains approximately 2 minutes in full-term neonates and older children 3

Clinical Implications of Short Half-Life

  • The extremely short half-life necessitates continuous intravenous infusion rather than bolus dosing for sustained therapeutic effect 1
  • Hemodynamic effects dissipate rapidly upon discontinuation, typically within minutes 1, 4
  • Dose titration is always necessary due to wide inter-patient variability in response, with the short half-life allowing rapid adjustment 1
  • The brief half-life provides a safety advantage, as adverse effects (tachycardia, arrhythmias, hypotension) resolve quickly after stopping or reducing the infusion 5

Metabolism and Excretion

  • Primary metabolic pathways: Methylation of the catechol ring and conjugation 1
  • Major urinary excretion products: Conjugates of dobutamine and 3-O-methyl dobutamine 1
  • The 3-O-methyl derivative is pharmacologically inactive 1

References

Research

Dobutamine stress echocardiography.

European heart journal, 1997

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.